Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | DUT | P33316 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4387677 | 1.00 | KMT2A (0.35) | KMT2AMEN1MAPTHSD17B10DUT | |
| SCHEMBL4386210 | 0.91 | KMT2A (0.36) | KMT2AMEN1MAPTHSD17B10DUT | |
| SCHEMBL4386214 | 0.91 | KMT2A (0.36) | KMT2AMEN1MAPTHSD17B10DUT | |
| SCHEMBL4389603 | 0.91 | KMT2A (0.36) | KMT2AMEN1MAPTHSD17B10DUT | |
| SCHEMBL4389606 | 0.91 | KMT2A (0.36) | KMT2AMEN1MAPTHSD17B10DUT | |
| SCHEMBL4387944 | 0.85 | KMT2A (0.39) | KMT2AMEN1MAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL4387941 | 0.85 | KMT2A (0.39) | KMT2AMEN1MAPTHSD17B10SMN1; SMN2 | |
| SCHEMBL4388105 | 0.84 | HRH3 (0.44) | — | |
| SCHEMBL4388568 | 0.84 | HRH3 (0.40) | — | |
| SCHEMBL4388102 | 0.84 | HRH3 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181948-A1 | DIAMINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181948-A1 | DIAMINE DERIVATIVE | ARG1, PRMT5, PRMT1 | KMT2A 441/4885MEN1 3396/4885MAPT 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.